Medibank Private (MPL) AI Stock Analysis

• Market Cap: $13.83B
• Dividend Yield: 3.43%
• Average Volume (3M): 5.36M
• Price to Earnings (P/E): 28.2
• Beta (1Y): 0.33
• Revenue Growth: 5.21%
• EPS Growth: -21.15%
• Country: AU
• Employees: 3,220
• Sector: Financial
• Sector Strength: 78
• Industry: Insurance - Diversified
• EPS (TTM): 0.11
• Shares Outstanding: 2,754,003,200
• 10 Day Avg. Volume: 4,465,418
• 30 Day Avg. Volume: 5,360,823
• PEG Ratio: N/A
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 22.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.99
• Price Target Upside: -0.51% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 8

• Rating: 73 Outperform
• Price Target: AU$5.50 ▲(9.56%Upside)

Medibank Private Ltd. has a strong financial foundation with robust revenue growth and a stable balance sheet, contributing significantly to the overall score. Technical analysis further supports a positive outlook with strong upward price trends, though caution is advised due to the potential overbought signals. The valuation presents a mixed picture with a high P/E ratio but an attractive dividend yield, suggesting potential overvaluation but rewarding income investors.

Medibank Private Business Overview & Revenue Model

Company Description

Medibank Private Limited provides private health insurance and health services in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers members with health cover for hospital treatments; and ancillary cover, which provides members with health cover for healthcare services, such as dental, optical, and physiotherapy. This segment also offers health insurance products to overseas visitors and overseas students. The Medibank Health segment provides health management and in-home care services, as well as a range of telehealth services to government and corporate customers; and distributes travel, life, and pet insurance products. The company underwrites its health insurance products under the Medibank and ahm brands Medibank Private Limited was founded in 1976 and is based in Docklands, Australia.

How the Company Makes Money

Medibank Private generates revenue primarily through the sale of health insurance policies to individuals and corporate clients. The company's income is derived from premium payments made by its members for hospital and extras cover, which provide access to a wide range of healthcare services. Additionally, Medibank earns money through its Health Services segment, which offers diversified health solutions such as telehealth, mental health support, and preventative health programs. Medibank also benefits from investment income, as it strategically manages a portfolio of financial assets to ensure liquidity and profitability. Key factors contributing to Medibank's earnings include regulatory policies in the Australian healthcare sector, customer retention strategies, and partnerships with healthcare providers to deliver cost-effective and quality health services.

Medibank Private Financial Statement Overview

Summary

Medibank Private Ltd. demonstrates a solid financial performance with strong revenue growth and profitability, despite challenges in operational efficiency. The balance sheet is robust with low leverage and efficient equity utilization, while cash flow generation shows significant improvement. The company is well-positioned to leverage its financial stability for future growth, though attention to operating expenses is advised.

Income Statement

Medibank Private Ltd. shows consistent revenue growth with a 7.52% increase in the latest year. The gross profit margin remains strong at 100%, indicating effective cost management. However, the decline in EBIT margin from 9.79% to 0.09% and net profit margin from 6.85% to 6.14% suggests pressure on operational efficiency. Despite these challenges, the company's EBITDA margin improved significantly, reflecting better underlying profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 49.21%. The debt-to-equity ratio is low at 0.09, indicating low financial leverage, and ROE is solid at 21.37%, showing effective utilization of equity. Overall, the balance sheet reflects stability and a conservative financial structure, minimizing potential risk from debt.

Cash Flow

Medibank's free cash flow grew substantially by 274.7%, highlighting improved cash generation. The operating cash flow to net income ratio is robust at 1.76, indicating strong cash conversion. However, the free cash flow to net income ratio of 1.65 suggests a potential need to optimize capital expenditures to maintain this positive trend.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	8.02B	7.46B	7.20B	6.98B	6.83B
Gross Profit	8.02B	7.46B	7.20B	6.98B	6.83B
EBITDA	724.20M	520.60M	635.10M	0.00	0.00
Net Income	492.50M	511.10M	393.90M	441.20M	315.00M
Balance Sheet
Total Assets	4.69B	4.39B	4.55B	3.92B	3.75B
Cash, Cash Equivalents and Short-Term Investments	927.90M	420.60M	596.70M	671.70M	871.40M
Total Debt	218.30M	55.30M	76.90M	93.40M	109.20M
Total Liabilities	2.38B	2.30B	2.61B	2.02B	1.95B
Stockholders Equity	2.31B	2.08B	1.95B	1.91B	1.80B
Cash Flow
Free Cash Flow	810.90M	216.30M	927.60M	463.10M	570.90M
Operating Cash Flow	868.50M	258.20M	962.70M	498.20M	600.20M
Investing Cash Flow	-110.80M	-15.20M	-637.80M	-322.10M	81.40M
Financing Cash Flow	-487.30M	-419.10M	-399.90M	-375.80M	-466.70M

Medibank Private Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MPL, the sentiment is Neutral. The current price of 5.02 is below the 20-day moving average (MA) of 5.04, above the 50-day MA of 4.91, and above the 200-day MA of 4.19, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 51.72 is Neutral, neither overbought nor oversold. The STOCH value of 57.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:MPL.

Medibank Private Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MPL	73 Outperform	$13.83B	28.23	20.97%	3.43%	5.21%	-21.15%
Sector *	58 Neutral	HK$91.35B	5.46	-3.21%	5.54%	7.36%	-55.21%
A5H	―	€2.29B	32.18	7.96%	1.43%	―	―
IAUGF	―	$13.17B	15.66	18.88%	2.77%	―	―
3GU	―	€2.00B	19.04	15.78%	3.99%	―	―
QBEIF	―	$22.74B	13.11	17.21%	3.78%	―	―
SNMYF	―	$14.61B	16.07	9.52%	2.75%	―	―

Medibank Private Corporate Events

AustralianSuper Increases Stake in Medibank Private

AustralianSuper Pty Ltd has increased its voting power in Medibank Private Limited from 6.73% to 7.78%, reflecting a significant change in the substantial holding of the company. This change in voting power indicates a strengthened position for AustralianSuper within Medibank, potentially impacting the company’s governance and strategic decisions.

The most recent analyst rating on (AU:MPL) stock is a Hold with a A$3.80 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.

AustralianSuper Increases Stake in Medibank Private

AustralianSuper Pty Ltd has increased its voting power in Medibank Private Limited from 5.57% to 6.73%, reflecting a significant change in its stake in the company. This change in substantial holding could influence Medibank’s shareholder dynamics and potentially impact its strategic decisions, highlighting AustralianSuper’s growing influence in the company’s governance.

The most recent analyst rating on (AU:MPL) stock is a Hold with a A$3.80 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.

Medibank Private Announces Key Dates for Fiscal Year 2025

Medibank Private Limited has announced key dates for the fiscal year ending June 30, 2025, including the release of its full-year results on August 28, 2025, followed by a teleconference and webcast briefing. The company also provided details on its final dividend payment schedule and the date for its annual general meeting, highlighting its commitment to transparency and shareholder engagement.

The most recent analyst rating on (AU:MPL) stock is a Hold with a A$3.80 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.